itpr1  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Alomone Labs itpr1
    Increase in the proportion of B cells, CD4 + T cells and CD8 + CD45RO + T cells among PBMCs from patient 1 (2 × 10 5 cells) following stimulation with <t>ITPR1</t> (10 μg/ml) ( orange outlines ) compared with stimulation with GFAP (10 μg/ml) and compared with healthy donor PBMCs stimulated with the same amount of ITPR1 or GFAP, respectively
    Itpr1, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/itpr1/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    itpr1 - by Bioz Stars, 2022-07
    93/100 stars

    Images

    1) Product Images from "Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy"

    Article Title: Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy

    Journal: Journal of Neuroinflammation

    doi: 10.1186/s12974-016-0737-x

    Increase in the proportion of B cells, CD4 + T cells and CD8 + CD45RO + T cells among PBMCs from patient 1 (2 × 10 5 cells) following stimulation with ITPR1 (10 μg/ml) ( orange outlines ) compared with stimulation with GFAP (10 μg/ml) and compared with healthy donor PBMCs stimulated with the same amount of ITPR1 or GFAP, respectively
    Figure Legend Snippet: Increase in the proportion of B cells, CD4 + T cells and CD8 + CD45RO + T cells among PBMCs from patient 1 (2 × 10 5 cells) following stimulation with ITPR1 (10 μg/ml) ( orange outlines ) compared with stimulation with GFAP (10 μg/ml) and compared with healthy donor PBMCs stimulated with the same amount of ITPR1 or GFAP, respectively

    Techniques Used:

    Expression of ITPR1 in the spinal cord ( a , e – g ), sural nerve ( h ) and dorsal root ganglia (DRG) ( b – d , i – j ) of adult mouse ( a , d ), rat ( b – c , e – f , i – j ) and rhesus monkey ( g – h ) and as detected by in situ hybridization ( a , b , e ) and immunostaining ( c – d , f – j ), and binding of IgG from the patient’s CSF ( i ) and serum ( j ) to sensory neuron somata in rat DRG as detected by indirect immunofluorescence. A polyclonal rabbit antibody to ITPR1 (Dianova) and an AlexaFluor®568-labelled goat anti-rabbit IgG secondary antibody were used to detect ITPR1 expression ( red ). A fluorescein isothiocyanate-labelled goat anti-human IgG antibody was used to visualize bound patient IgG ( green ). Yellow areas in j indicate overlay of the patient’s IgG and the commercial ITPR1 antibody. a Taken from the Allen Spinal Cord Atlas [ 64 ] ( http://mousespinal.brain-map.org/ ). b , c and e Reproduced from Dent et al. [ 2 ] with kind permission of the publisher , d from Zhuang et al. [ 5 ] (made available under the Creative Commons CC0 public domain dedication; https://creativecommons.org/publicdomain/zero/1.0/ ) , and f from Sharp et al. [ 3 ] with kind permission of the publisher. DH dorsal horn, IP3R inositol-1,4,5 trisphosphate receptor
    Figure Legend Snippet: Expression of ITPR1 in the spinal cord ( a , e – g ), sural nerve ( h ) and dorsal root ganglia (DRG) ( b – d , i – j ) of adult mouse ( a , d ), rat ( b – c , e – f , i – j ) and rhesus monkey ( g – h ) and as detected by in situ hybridization ( a , b , e ) and immunostaining ( c – d , f – j ), and binding of IgG from the patient’s CSF ( i ) and serum ( j ) to sensory neuron somata in rat DRG as detected by indirect immunofluorescence. A polyclonal rabbit antibody to ITPR1 (Dianova) and an AlexaFluor®568-labelled goat anti-rabbit IgG secondary antibody were used to detect ITPR1 expression ( red ). A fluorescein isothiocyanate-labelled goat anti-human IgG antibody was used to visualize bound patient IgG ( green ). Yellow areas in j indicate overlay of the patient’s IgG and the commercial ITPR1 antibody. a Taken from the Allen Spinal Cord Atlas [ 64 ] ( http://mousespinal.brain-map.org/ ). b , c and e Reproduced from Dent et al. [ 2 ] with kind permission of the publisher , d from Zhuang et al. [ 5 ] (made available under the Creative Commons CC0 public domain dedication; https://creativecommons.org/publicdomain/zero/1.0/ ) , and f from Sharp et al. [ 3 ] with kind permission of the publisher. DH dorsal horn, IP3R inositol-1,4,5 trisphosphate receptor

    Techniques Used: Expressing, In Situ Hybridization, Immunostaining, Binding Assay, Immunofluorescence

    ITPR1-specific antibody index
    Figure Legend Snippet: ITPR1-specific antibody index

    Techniques Used:

    ITPR1 is expressed in a subset of carcinomas of the lung. a Quantitative Western blot analysis showing ITPR1 expression as percentage of the ITPR1 expression in normal human bronchial epithelial (NHBE) cells, in the small cell lung cancer cell line H1339 and in the non-small cell lung cancer cell line HCC. The expression of IP3R was increased with H1339 showing the highest expression ( n = 4, * P
    Figure Legend Snippet: ITPR1 is expressed in a subset of carcinomas of the lung. a Quantitative Western blot analysis showing ITPR1 expression as percentage of the ITPR1 expression in normal human bronchial epithelial (NHBE) cells, in the small cell lung cancer cell line H1339 and in the non-small cell lung cancer cell line HCC. The expression of IP3R was increased with H1339 showing the highest expression ( n = 4, * P

    Techniques Used: Western Blot, Expressing

    ITPR1-IgG as detected by a immunohistochemistry, b a dot-blot assay and c , d a cell-based assay (exemplary findings). a Binding of patient serum IgG and of a commercial antibody to ITPR1 to formalin-fixed mouse (as well as rat and primate, not shown) cerebellum tissue sections ( MoL molecular layer, PCL purkinje cell layer). Binding of patient IgG is depicted in green (goat anti-human IgG Alexa Fluor® 488); binding of a commercial rabbit anti-ITPR1 antibody in red (goat anti-rabbit IgG Alexa Fluor® 568); yellow indicates binding of both antibodies. Cell nuclei were stained by 4',6-diamidino-2-phenylindole ( blue colour ). b Binding of IgG from the patient’s serum and from two previously reported ITPR1-IgG-positive patients [ 1 ] to purified native ITPR1 from rat brain in a dot-blot assay; by contrast, sera from four healthy and disease controls did not bind to ITPR1. A commercial goat anti-human IgG antibody labelled with IRdye®700 (Rockland, Limerick, PA) was used to detect bound patient IgG. c Binding of patient IgG to cells transfected with mouse ITPR1 ( left ) but not to mock-transfected HEK293 cells used as control substrate ( right ). Binding of patient IgG was visualized using a goat anti-human IgG secondary antibody labelled with fluorescein isothiocyanate. See the “ Methods ” section for details. ACA autoimmune cerebellar ataxia, PEX plasma exchange
    Figure Legend Snippet: ITPR1-IgG as detected by a immunohistochemistry, b a dot-blot assay and c , d a cell-based assay (exemplary findings). a Binding of patient serum IgG and of a commercial antibody to ITPR1 to formalin-fixed mouse (as well as rat and primate, not shown) cerebellum tissue sections ( MoL molecular layer, PCL purkinje cell layer). Binding of patient IgG is depicted in green (goat anti-human IgG Alexa Fluor® 488); binding of a commercial rabbit anti-ITPR1 antibody in red (goat anti-rabbit IgG Alexa Fluor® 568); yellow indicates binding of both antibodies. Cell nuclei were stained by 4',6-diamidino-2-phenylindole ( blue colour ). b Binding of IgG from the patient’s serum and from two previously reported ITPR1-IgG-positive patients [ 1 ] to purified native ITPR1 from rat brain in a dot-blot assay; by contrast, sera from four healthy and disease controls did not bind to ITPR1. A commercial goat anti-human IgG antibody labelled with IRdye®700 (Rockland, Limerick, PA) was used to detect bound patient IgG. c Binding of patient IgG to cells transfected with mouse ITPR1 ( left ) but not to mock-transfected HEK293 cells used as control substrate ( right ). Binding of patient IgG was visualized using a goat anti-human IgG secondary antibody labelled with fluorescein isothiocyanate. See the “ Methods ” section for details. ACA autoimmune cerebellar ataxia, PEX plasma exchange

    Techniques Used: Immunohistochemistry, Dot Blot, Cell Based Assay, Binding Assay, Staining, Purification, Transfection

    ITPR1-IgG in the CSF. Perfect overlap of the patient IgG from a CSF sample (patient 1) with a commercial antibody to ITPR1 as detected by IHC on a murine cerebellum tissue section. Bound patient IgG is depicted in green (Alexa Fluor® 488) and binding of the commercial anti-ITPR1 antibody in red (Alexa Fluor® 568); yellow indicates areas stained by both antibodies. Cell nuclei were stained by 4',6-diamidino-2-phenylindole ( blue )
    Figure Legend Snippet: ITPR1-IgG in the CSF. Perfect overlap of the patient IgG from a CSF sample (patient 1) with a commercial antibody to ITPR1 as detected by IHC on a murine cerebellum tissue section. Bound patient IgG is depicted in green (Alexa Fluor® 488) and binding of the commercial anti-ITPR1 antibody in red (Alexa Fluor® 568); yellow indicates areas stained by both antibodies. Cell nuclei were stained by 4',6-diamidino-2-phenylindole ( blue )

    Techniques Used: Immunohistochemistry, Binding Assay, Staining

    3 H-thymidine uptake (cpm; mean of three stimulations) in proliferating PBMCs from patient 1 and from a healthy control following stimulation with ITPR1 or GFAP, respectively. a Note the significantly higher 3 H-thymidine uptake in patient PBMCs stimulated with ITPR1 than in the healthy donor; by contrast, no difference was noted after stimulation with GFAP or with PBS. b After subtraction of non-antigen-specific, GFAP-induced proliferation, a difference (Δcpm) between patient and healthy control of more than 600 cpm or 340 % was noted following ITPR1 stimulation
    Figure Legend Snippet: 3 H-thymidine uptake (cpm; mean of three stimulations) in proliferating PBMCs from patient 1 and from a healthy control following stimulation with ITPR1 or GFAP, respectively. a Note the significantly higher 3 H-thymidine uptake in patient PBMCs stimulated with ITPR1 than in the healthy donor; by contrast, no difference was noted after stimulation with GFAP or with PBS. b After subtraction of non-antigen-specific, GFAP-induced proliferation, a difference (Δcpm) between patient and healthy control of more than 600 cpm or 340 % was noted following ITPR1 stimulation

    Techniques Used:

    ITPR1 class and subclass analysis revealed IgG1 a and IgA ( b , inset) antibodies in patient 1 and IgG2 antibodies in patient 2 (as well as in patient 3, not shown) b
    Figure Legend Snippet: ITPR1 class and subclass analysis revealed IgG1 a and IgA ( b , inset) antibodies in patient 1 and IgG2 antibodies in patient 2 (as well as in patient 3, not shown) b

    Techniques Used:

    2) Product Images from "Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy"

    Article Title: Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy

    Journal: Journal of Neuroinflammation

    doi: 10.1186/s12974-016-0737-x

    Increase in the proportion of B cells, CD4 + T cells and CD8 + CD45RO + T cells among PBMCs from patient 1 (2 × 10 5 cells) following stimulation with ITPR1 (10 μg/ml) ( orange outlines ) compared with stimulation with GFAP (10 μg/ml) and compared with healthy donor PBMCs stimulated with the same amount of ITPR1 or GFAP, respectively
    Figure Legend Snippet: Increase in the proportion of B cells, CD4 + T cells and CD8 + CD45RO + T cells among PBMCs from patient 1 (2 × 10 5 cells) following stimulation with ITPR1 (10 μg/ml) ( orange outlines ) compared with stimulation with GFAP (10 μg/ml) and compared with healthy donor PBMCs stimulated with the same amount of ITPR1 or GFAP, respectively

    Techniques Used:

    Expression of ITPR1 in the spinal cord ( a , e – g ), sural nerve ( h ) and dorsal root ganglia (DRG) ( b – d , i – j ) of adult mouse ( a , d ), rat ( b – c , e – f , i – j ) and rhesus monkey ( g – h ) and as detected by in situ hybridization ( a , b , e ) and immunostaining ( c – d , f – j ), and binding of IgG from the patient’s CSF ( i ) and serum ( j ) to sensory neuron somata in rat DRG as detected by indirect immunofluorescence. A polyclonal rabbit antibody to ITPR1 (Dianova) and an AlexaFluor®568-labelled goat anti-rabbit IgG secondary antibody were used to detect ITPR1 expression ( red ). A fluorescein isothiocyanate-labelled goat anti-human IgG antibody was used to visualize bound patient IgG ( green ). Yellow areas in j indicate overlay of the patient’s IgG and the commercial ITPR1 antibody. a Taken from the Allen Spinal Cord Atlas [ 64 ] ( http://mousespinal.brain-map.org/ ). b , c and e Reproduced from Dent et al. [ 2 ] with kind permission of the publisher , d from Zhuang et al. [ 5 ] (made available under the Creative Commons CC0 public domain dedication; https://creativecommons.org/publicdomain/zero/1.0/ ) , and f from Sharp et al. [ 3 ] with kind permission of the publisher. DH dorsal horn, IP3R inositol-1,4,5 trisphosphate receptor
    Figure Legend Snippet: Expression of ITPR1 in the spinal cord ( a , e – g ), sural nerve ( h ) and dorsal root ganglia (DRG) ( b – d , i – j ) of adult mouse ( a , d ), rat ( b – c , e – f , i – j ) and rhesus monkey ( g – h ) and as detected by in situ hybridization ( a , b , e ) and immunostaining ( c – d , f – j ), and binding of IgG from the patient’s CSF ( i ) and serum ( j ) to sensory neuron somata in rat DRG as detected by indirect immunofluorescence. A polyclonal rabbit antibody to ITPR1 (Dianova) and an AlexaFluor®568-labelled goat anti-rabbit IgG secondary antibody were used to detect ITPR1 expression ( red ). A fluorescein isothiocyanate-labelled goat anti-human IgG antibody was used to visualize bound patient IgG ( green ). Yellow areas in j indicate overlay of the patient’s IgG and the commercial ITPR1 antibody. a Taken from the Allen Spinal Cord Atlas [ 64 ] ( http://mousespinal.brain-map.org/ ). b , c and e Reproduced from Dent et al. [ 2 ] with kind permission of the publisher , d from Zhuang et al. [ 5 ] (made available under the Creative Commons CC0 public domain dedication; https://creativecommons.org/publicdomain/zero/1.0/ ) , and f from Sharp et al. [ 3 ] with kind permission of the publisher. DH dorsal horn, IP3R inositol-1,4,5 trisphosphate receptor

    Techniques Used: Expressing, In Situ Hybridization, Immunostaining, Binding Assay, Immunofluorescence

    ITPR1-specific antibody index
    Figure Legend Snippet: ITPR1-specific antibody index

    Techniques Used:

    ITPR1 is expressed in a subset of carcinomas of the lung. a Quantitative Western blot analysis showing ITPR1 expression as percentage of the ITPR1 expression in normal human bronchial epithelial (NHBE) cells, in the small cell lung cancer cell line H1339 and in the non-small cell lung cancer cell line HCC. The expression of IP3R was increased with H1339 showing the highest expression ( n = 4, * P
    Figure Legend Snippet: ITPR1 is expressed in a subset of carcinomas of the lung. a Quantitative Western blot analysis showing ITPR1 expression as percentage of the ITPR1 expression in normal human bronchial epithelial (NHBE) cells, in the small cell lung cancer cell line H1339 and in the non-small cell lung cancer cell line HCC. The expression of IP3R was increased with H1339 showing the highest expression ( n = 4, * P

    Techniques Used: Western Blot, Expressing

    ITPR1-IgG as detected by a immunohistochemistry, b a dot-blot assay and c , d a cell-based assay (exemplary findings). a Binding of patient serum IgG and of a commercial antibody to ITPR1 to formalin-fixed mouse (as well as rat and primate, not shown) cerebellum tissue sections ( MoL molecular layer, PCL purkinje cell layer). Binding of patient IgG is depicted in green (goat anti-human IgG Alexa Fluor® 488); binding of a commercial rabbit anti-ITPR1 antibody in red (goat anti-rabbit IgG Alexa Fluor® 568); yellow indicates binding of both antibodies. Cell nuclei were stained by 4',6-diamidino-2-phenylindole ( blue colour ). b Binding of IgG from the patient’s serum and from two previously reported ITPR1-IgG-positive patients [ 1 ] to purified native ITPR1 from rat brain in a dot-blot assay; by contrast, sera from four healthy and disease controls did not bind to ITPR1. A commercial goat anti-human IgG antibody labelled with IRdye®700 (Rockland, Limerick, PA) was used to detect bound patient IgG. c Binding of patient IgG to cells transfected with mouse ITPR1 ( left ) but not to mock-transfected HEK293 cells used as control substrate ( right ). Binding of patient IgG was visualized using a goat anti-human IgG secondary antibody labelled with fluorescein isothiocyanate. See the “ Methods ” section for details. ACA autoimmune cerebellar ataxia, PEX plasma exchange
    Figure Legend Snippet: ITPR1-IgG as detected by a immunohistochemistry, b a dot-blot assay and c , d a cell-based assay (exemplary findings). a Binding of patient serum IgG and of a commercial antibody to ITPR1 to formalin-fixed mouse (as well as rat and primate, not shown) cerebellum tissue sections ( MoL molecular layer, PCL purkinje cell layer). Binding of patient IgG is depicted in green (goat anti-human IgG Alexa Fluor® 488); binding of a commercial rabbit anti-ITPR1 antibody in red (goat anti-rabbit IgG Alexa Fluor® 568); yellow indicates binding of both antibodies. Cell nuclei were stained by 4',6-diamidino-2-phenylindole ( blue colour ). b Binding of IgG from the patient’s serum and from two previously reported ITPR1-IgG-positive patients [ 1 ] to purified native ITPR1 from rat brain in a dot-blot assay; by contrast, sera from four healthy and disease controls did not bind to ITPR1. A commercial goat anti-human IgG antibody labelled with IRdye®700 (Rockland, Limerick, PA) was used to detect bound patient IgG. c Binding of patient IgG to cells transfected with mouse ITPR1 ( left ) but not to mock-transfected HEK293 cells used as control substrate ( right ). Binding of patient IgG was visualized using a goat anti-human IgG secondary antibody labelled with fluorescein isothiocyanate. See the “ Methods ” section for details. ACA autoimmune cerebellar ataxia, PEX plasma exchange

    Techniques Used: Immunohistochemistry, Dot Blot, Cell Based Assay, Binding Assay, Staining, Purification, Transfection

    ITPR1-IgG in the CSF. Perfect overlap of the patient IgG from a CSF sample (patient 1) with a commercial antibody to ITPR1 as detected by IHC on a murine cerebellum tissue section. Bound patient IgG is depicted in green (Alexa Fluor® 488) and binding of the commercial anti-ITPR1 antibody in red (Alexa Fluor® 568); yellow indicates areas stained by both antibodies. Cell nuclei were stained by 4',6-diamidino-2-phenylindole ( blue )
    Figure Legend Snippet: ITPR1-IgG in the CSF. Perfect overlap of the patient IgG from a CSF sample (patient 1) with a commercial antibody to ITPR1 as detected by IHC on a murine cerebellum tissue section. Bound patient IgG is depicted in green (Alexa Fluor® 488) and binding of the commercial anti-ITPR1 antibody in red (Alexa Fluor® 568); yellow indicates areas stained by both antibodies. Cell nuclei were stained by 4',6-diamidino-2-phenylindole ( blue )

    Techniques Used: Immunohistochemistry, Binding Assay, Staining

    3 H-thymidine uptake (cpm; mean of three stimulations) in proliferating PBMCs from patient 1 and from a healthy control following stimulation with ITPR1 or GFAP, respectively. a Note the significantly higher 3 H-thymidine uptake in patient PBMCs stimulated with ITPR1 than in the healthy donor; by contrast, no difference was noted after stimulation with GFAP or with PBS. b After subtraction of non-antigen-specific, GFAP-induced proliferation, a difference (Δcpm) between patient and healthy control of more than 600 cpm or 340 % was noted following ITPR1 stimulation
    Figure Legend Snippet: 3 H-thymidine uptake (cpm; mean of three stimulations) in proliferating PBMCs from patient 1 and from a healthy control following stimulation with ITPR1 or GFAP, respectively. a Note the significantly higher 3 H-thymidine uptake in patient PBMCs stimulated with ITPR1 than in the healthy donor; by contrast, no difference was noted after stimulation with GFAP or with PBS. b After subtraction of non-antigen-specific, GFAP-induced proliferation, a difference (Δcpm) between patient and healthy control of more than 600 cpm or 340 % was noted following ITPR1 stimulation

    Techniques Used:

    ITPR1 class and subclass analysis revealed IgG1 a and IgA ( b , inset) antibodies in patient 1 and IgG2 antibodies in patient 2 (as well as in patient 3, not shown) b
    Figure Legend Snippet: ITPR1 class and subclass analysis revealed IgG1 a and IgA ( b , inset) antibodies in patient 1 and IgG2 antibodies in patient 2 (as well as in patient 3, not shown) b

    Techniques Used:

    3) Product Images from "Generation of a transgenic zebrafish model of Tauopathy using a novel promoter element derived from the zebrafish eno2 gene"

    Article Title: Generation of a transgenic zebrafish model of Tauopathy using a novel promoter element derived from the zebrafish eno2 gene

    Journal: Nucleic Acids Research

    doi: 10.1093/nar/gkm608

    GFP expression in the brains of adult Tg( eno2:GFP ) zebrafish. ( A ) Parasagittal sections of Tg( eno2:GFP ) Pt404 (upper panel) and wild-type (lower panel) brain were labelled with an antibody to GFP. Bound antibody was detected using a histochemical reaction with a red product and nuclei were labelled with a blue counterstain. GFP expression was apparent throughout the brain of transgenic adults. ( B ) High-power view of medullary reticular formation of Tg( eno2:GFP ) Pt404 zebrafish brain, showing GFP expression in cells with neuronal morphology. The arrows show GFP-expressing neurons with axons in the plane of the section. ( C – F ) Double label confocal images of Tg( eno2:GFP ) Pt404 adult brains. Each panel consists of a set of three images: (i) Upper image; red: a cell type-specific marker of interest was localized using specific antibodies. C: Medulla; ChAT, choline acetyltransferase; cholinergic neurons; D: Olfactory bulb; TH, tyrosine hydroxylase; dopaminergic neurons; E: cerebellum; IP3R1, IP3 receptor 1; cerebellar Purkinje cells; D: thalamus; GABA, γ-amino butyric acid; inhibitory neurons; (ii) Middle image, green: GFP expression was localized in the same sections using a GFP antibody; (iii) Lower image: the merged images show co-localization of GFP and the cell type-specific marker (yellow), and were counterstained with DAPI to show nuclei (blue). The scale bar (10 µm) for each set of images is shown in the lower panel.
    Figure Legend Snippet: GFP expression in the brains of adult Tg( eno2:GFP ) zebrafish. ( A ) Parasagittal sections of Tg( eno2:GFP ) Pt404 (upper panel) and wild-type (lower panel) brain were labelled with an antibody to GFP. Bound antibody was detected using a histochemical reaction with a red product and nuclei were labelled with a blue counterstain. GFP expression was apparent throughout the brain of transgenic adults. ( B ) High-power view of medullary reticular formation of Tg( eno2:GFP ) Pt404 zebrafish brain, showing GFP expression in cells with neuronal morphology. The arrows show GFP-expressing neurons with axons in the plane of the section. ( C – F ) Double label confocal images of Tg( eno2:GFP ) Pt404 adult brains. Each panel consists of a set of three images: (i) Upper image; red: a cell type-specific marker of interest was localized using specific antibodies. C: Medulla; ChAT, choline acetyltransferase; cholinergic neurons; D: Olfactory bulb; TH, tyrosine hydroxylase; dopaminergic neurons; E: cerebellum; IP3R1, IP3 receptor 1; cerebellar Purkinje cells; D: thalamus; GABA, γ-amino butyric acid; inhibitory neurons; (ii) Middle image, green: GFP expression was localized in the same sections using a GFP antibody; (iii) Lower image: the merged images show co-localization of GFP and the cell type-specific marker (yellow), and were counterstained with DAPI to show nuclei (blue). The scale bar (10 µm) for each set of images is shown in the lower panel.

    Techniques Used: Expressing, Transgenic Assay, Marker

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • itpr1  (Alomone Labs)
    93
    Alomone Labs itpr1
    Increase in the proportion of B cells, CD4 + T cells and CD8 + CD45RO + T cells among PBMCs from patient 1 (2 × 10 5 cells) following stimulation with <t>ITPR1</t> (10 μg/ml) ( orange outlines ) compared with stimulation with GFAP (10 μg/ml) and compared with healthy donor PBMCs stimulated with the same amount of ITPR1 or GFAP, respectively
    Itpr1, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/itpr1/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    itpr1 - by Bioz Stars, 2022-07
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Increase in the proportion of B cells, CD4 + T cells and CD8 + CD45RO + T cells among PBMCs from patient 1 (2 × 10 5 cells) following stimulation with ITPR1 (10 μg/ml) ( orange outlines ) compared with stimulation with GFAP (10 μg/ml) and compared with healthy donor PBMCs stimulated with the same amount of ITPR1 or GFAP, respectively

    Journal: Journal of Neuroinflammation

    Article Title: Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy

    doi: 10.1186/s12974-016-0737-x

    Figure Lengend Snippet: Increase in the proportion of B cells, CD4 + T cells and CD8 + CD45RO + T cells among PBMCs from patient 1 (2 × 10 5 cells) following stimulation with ITPR1 (10 μg/ml) ( orange outlines ) compared with stimulation with GFAP (10 μg/ml) and compared with healthy donor PBMCs stimulated with the same amount of ITPR1 or GFAP, respectively

    Article Snippet: To exclude non-specific binding or cross-reactivity of the commercial antibody used, we employed a second commercial antibody to ITPR1 (Alomone Labs, Jerusalem, Israel) resulting in an identical binding pattern (not shown).

    Techniques:

    Expression of ITPR1 in the spinal cord ( a , e – g ), sural nerve ( h ) and dorsal root ganglia (DRG) ( b – d , i – j ) of adult mouse ( a , d ), rat ( b – c , e – f , i – j ) and rhesus monkey ( g – h ) and as detected by in situ hybridization ( a , b , e ) and immunostaining ( c – d , f – j ), and binding of IgG from the patient’s CSF ( i ) and serum ( j ) to sensory neuron somata in rat DRG as detected by indirect immunofluorescence. A polyclonal rabbit antibody to ITPR1 (Dianova) and an AlexaFluor®568-labelled goat anti-rabbit IgG secondary antibody were used to detect ITPR1 expression ( red ). A fluorescein isothiocyanate-labelled goat anti-human IgG antibody was used to visualize bound patient IgG ( green ). Yellow areas in j indicate overlay of the patient’s IgG and the commercial ITPR1 antibody. a Taken from the Allen Spinal Cord Atlas [ 64 ] ( http://mousespinal.brain-map.org/ ). b , c and e Reproduced from Dent et al. [ 2 ] with kind permission of the publisher , d from Zhuang et al. [ 5 ] (made available under the Creative Commons CC0 public domain dedication; https://creativecommons.org/publicdomain/zero/1.0/ ) , and f from Sharp et al. [ 3 ] with kind permission of the publisher. DH dorsal horn, IP3R inositol-1,4,5 trisphosphate receptor

    Journal: Journal of Neuroinflammation

    Article Title: Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy

    doi: 10.1186/s12974-016-0737-x

    Figure Lengend Snippet: Expression of ITPR1 in the spinal cord ( a , e – g ), sural nerve ( h ) and dorsal root ganglia (DRG) ( b – d , i – j ) of adult mouse ( a , d ), rat ( b – c , e – f , i – j ) and rhesus monkey ( g – h ) and as detected by in situ hybridization ( a , b , e ) and immunostaining ( c – d , f – j ), and binding of IgG from the patient’s CSF ( i ) and serum ( j ) to sensory neuron somata in rat DRG as detected by indirect immunofluorescence. A polyclonal rabbit antibody to ITPR1 (Dianova) and an AlexaFluor®568-labelled goat anti-rabbit IgG secondary antibody were used to detect ITPR1 expression ( red ). A fluorescein isothiocyanate-labelled goat anti-human IgG antibody was used to visualize bound patient IgG ( green ). Yellow areas in j indicate overlay of the patient’s IgG and the commercial ITPR1 antibody. a Taken from the Allen Spinal Cord Atlas [ 64 ] ( http://mousespinal.brain-map.org/ ). b , c and e Reproduced from Dent et al. [ 2 ] with kind permission of the publisher , d from Zhuang et al. [ 5 ] (made available under the Creative Commons CC0 public domain dedication; https://creativecommons.org/publicdomain/zero/1.0/ ) , and f from Sharp et al. [ 3 ] with kind permission of the publisher. DH dorsal horn, IP3R inositol-1,4,5 trisphosphate receptor

    Article Snippet: To exclude non-specific binding or cross-reactivity of the commercial antibody used, we employed a second commercial antibody to ITPR1 (Alomone Labs, Jerusalem, Israel) resulting in an identical binding pattern (not shown).

    Techniques: Expressing, In Situ Hybridization, Immunostaining, Binding Assay, Immunofluorescence

    ITPR1-specific antibody index

    Journal: Journal of Neuroinflammation

    Article Title: Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy

    doi: 10.1186/s12974-016-0737-x

    Figure Lengend Snippet: ITPR1-specific antibody index

    Article Snippet: To exclude non-specific binding or cross-reactivity of the commercial antibody used, we employed a second commercial antibody to ITPR1 (Alomone Labs, Jerusalem, Israel) resulting in an identical binding pattern (not shown).

    Techniques:

    ITPR1 is expressed in a subset of carcinomas of the lung. a Quantitative Western blot analysis showing ITPR1 expression as percentage of the ITPR1 expression in normal human bronchial epithelial (NHBE) cells, in the small cell lung cancer cell line H1339 and in the non-small cell lung cancer cell line HCC. The expression of IP3R was increased with H1339 showing the highest expression ( n = 4, * P

    Journal: Journal of Neuroinflammation

    Article Title: Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy

    doi: 10.1186/s12974-016-0737-x

    Figure Lengend Snippet: ITPR1 is expressed in a subset of carcinomas of the lung. a Quantitative Western blot analysis showing ITPR1 expression as percentage of the ITPR1 expression in normal human bronchial epithelial (NHBE) cells, in the small cell lung cancer cell line H1339 and in the non-small cell lung cancer cell line HCC. The expression of IP3R was increased with H1339 showing the highest expression ( n = 4, * P

    Article Snippet: To exclude non-specific binding or cross-reactivity of the commercial antibody used, we employed a second commercial antibody to ITPR1 (Alomone Labs, Jerusalem, Israel) resulting in an identical binding pattern (not shown).

    Techniques: Western Blot, Expressing

    ITPR1-IgG as detected by a immunohistochemistry, b a dot-blot assay and c , d a cell-based assay (exemplary findings). a Binding of patient serum IgG and of a commercial antibody to ITPR1 to formalin-fixed mouse (as well as rat and primate, not shown) cerebellum tissue sections ( MoL molecular layer, PCL purkinje cell layer). Binding of patient IgG is depicted in green (goat anti-human IgG Alexa Fluor® 488); binding of a commercial rabbit anti-ITPR1 antibody in red (goat anti-rabbit IgG Alexa Fluor® 568); yellow indicates binding of both antibodies. Cell nuclei were stained by 4',6-diamidino-2-phenylindole ( blue colour ). b Binding of IgG from the patient’s serum and from two previously reported ITPR1-IgG-positive patients [ 1 ] to purified native ITPR1 from rat brain in a dot-blot assay; by contrast, sera from four healthy and disease controls did not bind to ITPR1. A commercial goat anti-human IgG antibody labelled with IRdye®700 (Rockland, Limerick, PA) was used to detect bound patient IgG. c Binding of patient IgG to cells transfected with mouse ITPR1 ( left ) but not to mock-transfected HEK293 cells used as control substrate ( right ). Binding of patient IgG was visualized using a goat anti-human IgG secondary antibody labelled with fluorescein isothiocyanate. See the “ Methods ” section for details. ACA autoimmune cerebellar ataxia, PEX plasma exchange

    Journal: Journal of Neuroinflammation

    Article Title: Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy

    doi: 10.1186/s12974-016-0737-x

    Figure Lengend Snippet: ITPR1-IgG as detected by a immunohistochemistry, b a dot-blot assay and c , d a cell-based assay (exemplary findings). a Binding of patient serum IgG and of a commercial antibody to ITPR1 to formalin-fixed mouse (as well as rat and primate, not shown) cerebellum tissue sections ( MoL molecular layer, PCL purkinje cell layer). Binding of patient IgG is depicted in green (goat anti-human IgG Alexa Fluor® 488); binding of a commercial rabbit anti-ITPR1 antibody in red (goat anti-rabbit IgG Alexa Fluor® 568); yellow indicates binding of both antibodies. Cell nuclei were stained by 4',6-diamidino-2-phenylindole ( blue colour ). b Binding of IgG from the patient’s serum and from two previously reported ITPR1-IgG-positive patients [ 1 ] to purified native ITPR1 from rat brain in a dot-blot assay; by contrast, sera from four healthy and disease controls did not bind to ITPR1. A commercial goat anti-human IgG antibody labelled with IRdye®700 (Rockland, Limerick, PA) was used to detect bound patient IgG. c Binding of patient IgG to cells transfected with mouse ITPR1 ( left ) but not to mock-transfected HEK293 cells used as control substrate ( right ). Binding of patient IgG was visualized using a goat anti-human IgG secondary antibody labelled with fluorescein isothiocyanate. See the “ Methods ” section for details. ACA autoimmune cerebellar ataxia, PEX plasma exchange

    Article Snippet: To exclude non-specific binding or cross-reactivity of the commercial antibody used, we employed a second commercial antibody to ITPR1 (Alomone Labs, Jerusalem, Israel) resulting in an identical binding pattern (not shown).

    Techniques: Immunohistochemistry, Dot Blot, Cell Based Assay, Binding Assay, Staining, Purification, Transfection

    ITPR1-IgG in the CSF. Perfect overlap of the patient IgG from a CSF sample (patient 1) with a commercial antibody to ITPR1 as detected by IHC on a murine cerebellum tissue section. Bound patient IgG is depicted in green (Alexa Fluor® 488) and binding of the commercial anti-ITPR1 antibody in red (Alexa Fluor® 568); yellow indicates areas stained by both antibodies. Cell nuclei were stained by 4',6-diamidino-2-phenylindole ( blue )

    Journal: Journal of Neuroinflammation

    Article Title: Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy

    doi: 10.1186/s12974-016-0737-x

    Figure Lengend Snippet: ITPR1-IgG in the CSF. Perfect overlap of the patient IgG from a CSF sample (patient 1) with a commercial antibody to ITPR1 as detected by IHC on a murine cerebellum tissue section. Bound patient IgG is depicted in green (Alexa Fluor® 488) and binding of the commercial anti-ITPR1 antibody in red (Alexa Fluor® 568); yellow indicates areas stained by both antibodies. Cell nuclei were stained by 4',6-diamidino-2-phenylindole ( blue )

    Article Snippet: To exclude non-specific binding or cross-reactivity of the commercial antibody used, we employed a second commercial antibody to ITPR1 (Alomone Labs, Jerusalem, Israel) resulting in an identical binding pattern (not shown).

    Techniques: Immunohistochemistry, Binding Assay, Staining

    3 H-thymidine uptake (cpm; mean of three stimulations) in proliferating PBMCs from patient 1 and from a healthy control following stimulation with ITPR1 or GFAP, respectively. a Note the significantly higher 3 H-thymidine uptake in patient PBMCs stimulated with ITPR1 than in the healthy donor; by contrast, no difference was noted after stimulation with GFAP or with PBS. b After subtraction of non-antigen-specific, GFAP-induced proliferation, a difference (Δcpm) between patient and healthy control of more than 600 cpm or 340 % was noted following ITPR1 stimulation

    Journal: Journal of Neuroinflammation

    Article Title: Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy

    doi: 10.1186/s12974-016-0737-x

    Figure Lengend Snippet: 3 H-thymidine uptake (cpm; mean of three stimulations) in proliferating PBMCs from patient 1 and from a healthy control following stimulation with ITPR1 or GFAP, respectively. a Note the significantly higher 3 H-thymidine uptake in patient PBMCs stimulated with ITPR1 than in the healthy donor; by contrast, no difference was noted after stimulation with GFAP or with PBS. b After subtraction of non-antigen-specific, GFAP-induced proliferation, a difference (Δcpm) between patient and healthy control of more than 600 cpm or 340 % was noted following ITPR1 stimulation

    Article Snippet: To exclude non-specific binding or cross-reactivity of the commercial antibody used, we employed a second commercial antibody to ITPR1 (Alomone Labs, Jerusalem, Israel) resulting in an identical binding pattern (not shown).

    Techniques:

    ITPR1 class and subclass analysis revealed IgG1 a and IgA ( b , inset) antibodies in patient 1 and IgG2 antibodies in patient 2 (as well as in patient 3, not shown) b

    Journal: Journal of Neuroinflammation

    Article Title: Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy

    doi: 10.1186/s12974-016-0737-x

    Figure Lengend Snippet: ITPR1 class and subclass analysis revealed IgG1 a and IgA ( b , inset) antibodies in patient 1 and IgG2 antibodies in patient 2 (as well as in patient 3, not shown) b

    Article Snippet: To exclude non-specific binding or cross-reactivity of the commercial antibody used, we employed a second commercial antibody to ITPR1 (Alomone Labs, Jerusalem, Israel) resulting in an identical binding pattern (not shown).

    Techniques:

    GFP expression in the brains of adult Tg( eno2:GFP ) zebrafish. ( A ) Parasagittal sections of Tg( eno2:GFP ) Pt404 (upper panel) and wild-type (lower panel) brain were labelled with an antibody to GFP. Bound antibody was detected using a histochemical reaction with a red product and nuclei were labelled with a blue counterstain. GFP expression was apparent throughout the brain of transgenic adults. ( B ) High-power view of medullary reticular formation of Tg( eno2:GFP ) Pt404 zebrafish brain, showing GFP expression in cells with neuronal morphology. The arrows show GFP-expressing neurons with axons in the plane of the section. ( C – F ) Double label confocal images of Tg( eno2:GFP ) Pt404 adult brains. Each panel consists of a set of three images: (i) Upper image; red: a cell type-specific marker of interest was localized using specific antibodies. C: Medulla; ChAT, choline acetyltransferase; cholinergic neurons; D: Olfactory bulb; TH, tyrosine hydroxylase; dopaminergic neurons; E: cerebellum; IP3R1, IP3 receptor 1; cerebellar Purkinje cells; D: thalamus; GABA, γ-amino butyric acid; inhibitory neurons; (ii) Middle image, green: GFP expression was localized in the same sections using a GFP antibody; (iii) Lower image: the merged images show co-localization of GFP and the cell type-specific marker (yellow), and were counterstained with DAPI to show nuclei (blue). The scale bar (10 µm) for each set of images is shown in the lower panel.

    Journal: Nucleic Acids Research

    Article Title: Generation of a transgenic zebrafish model of Tauopathy using a novel promoter element derived from the zebrafish eno2 gene

    doi: 10.1093/nar/gkm608

    Figure Lengend Snippet: GFP expression in the brains of adult Tg( eno2:GFP ) zebrafish. ( A ) Parasagittal sections of Tg( eno2:GFP ) Pt404 (upper panel) and wild-type (lower panel) brain were labelled with an antibody to GFP. Bound antibody was detected using a histochemical reaction with a red product and nuclei were labelled with a blue counterstain. GFP expression was apparent throughout the brain of transgenic adults. ( B ) High-power view of medullary reticular formation of Tg( eno2:GFP ) Pt404 zebrafish brain, showing GFP expression in cells with neuronal morphology. The arrows show GFP-expressing neurons with axons in the plane of the section. ( C – F ) Double label confocal images of Tg( eno2:GFP ) Pt404 adult brains. Each panel consists of a set of three images: (i) Upper image; red: a cell type-specific marker of interest was localized using specific antibodies. C: Medulla; ChAT, choline acetyltransferase; cholinergic neurons; D: Olfactory bulb; TH, tyrosine hydroxylase; dopaminergic neurons; E: cerebellum; IP3R1, IP3 receptor 1; cerebellar Purkinje cells; D: thalamus; GABA, γ-amino butyric acid; inhibitory neurons; (ii) Middle image, green: GFP expression was localized in the same sections using a GFP antibody; (iii) Lower image: the merged images show co-localization of GFP and the cell type-specific marker (yellow), and were counterstained with DAPI to show nuclei (blue). The scale bar (10 µm) for each set of images is shown in the lower panel.

    Article Snippet: Cryosections measuring 20 µm were incubated overnight at 4°C with primary antibody, diluted: 1:500 (GFP; cat# MAB3580 Chemicon, Temecula, CA, USA), 1:250 (ChAT; cat# AB144P, Chemicon; this antibody was incubated with sections for 72 h at 4°C), 1:100 (IP3R1; cat#ACC-019, Alomone Labs, Jerusalem, Israel), 1:1000 (GABA; cat# A2052, Sigma), 1:500 (Human Tau; cat#AHB0042, Biosource, Camarillo, CA, USA) or 1:500 (TH; cat# AB152, Chemicon), in carrier buffer (PBS, 1% goat or donkey serum, 1% BSA).

    Techniques: Expressing, Transgenic Assay, Marker

    Knockdown of TRPC7 decreased the activity of RyR2 and SERCA without affecting the activity of IP3R in mESC-CMs. Representative CaTs recorded from the control group a before and b after applying ryanodine. Representative CaTs recorded from TRPC7 knockdown group c before and d after applying ryanodine. e , f Bar charts showing the normalized frequency and the V max-upstroke calculated from a – d . The decrease of the frequency and the V max-upstroke caused by ryanodine was less in TRPC7 knockdown group. Representative CaTs recorded from the control group g before and h after applying thapsigargin (TG). Representative CaTs recorded from TRPC7 knockdown group i before and j after applying TG. k , l Bar charts showing the normalized frequency and V max-decay calculated from g – j . The decrease of the frequency and the V max-decay and amplitude caused by TG was less in TRPC7 knockdown group. Representative CaTs recorded from the control group m before and n after applying 2-aminoethoxydipheylborate (2-APB). Representative CaTs recorded from TRPC7 knockdown group o before and p after applying 2-APB. q , r Bar charts showing the normalized frequency and the V max-upstroke calculated from m – p . The decrease of the frequency and the V max-upstroke caused by 2-APB was similar between control and TRPC7 knockdown groups. Data were presented as mean ± SEM ( n = 10 cells; cells were from 3 independent batches of differentiation). * P

    Journal: Stem Cell Research & Therapy

    Article Title: TRPC7 regulates the electrophysiological functions of embryonic stem cell-derived cardiomyocytes

    doi: 10.1186/s13287-021-02308-7

    Figure Lengend Snippet: Knockdown of TRPC7 decreased the activity of RyR2 and SERCA without affecting the activity of IP3R in mESC-CMs. Representative CaTs recorded from the control group a before and b after applying ryanodine. Representative CaTs recorded from TRPC7 knockdown group c before and d after applying ryanodine. e , f Bar charts showing the normalized frequency and the V max-upstroke calculated from a – d . The decrease of the frequency and the V max-upstroke caused by ryanodine was less in TRPC7 knockdown group. Representative CaTs recorded from the control group g before and h after applying thapsigargin (TG). Representative CaTs recorded from TRPC7 knockdown group i before and j after applying TG. k , l Bar charts showing the normalized frequency and V max-decay calculated from g – j . The decrease of the frequency and the V max-decay and amplitude caused by TG was less in TRPC7 knockdown group. Representative CaTs recorded from the control group m before and n after applying 2-aminoethoxydipheylborate (2-APB). Representative CaTs recorded from TRPC7 knockdown group o before and p after applying 2-APB. q , r Bar charts showing the normalized frequency and the V max-upstroke calculated from m – p . The decrease of the frequency and the V max-upstroke caused by 2-APB was similar between control and TRPC7 knockdown groups. Data were presented as mean ± SEM ( n = 10 cells; cells were from 3 independent batches of differentiation). * P

    Article Snippet: Antibodies used were anti-TRPC7 1:500 (HPA031126, Sigma), anti-β-tubulin 1:1000 (15,115, Cell Signaling, Danvers, Massachusetts, USA), anti-HCN4 1:200 (APC-052, Alomone), anti-Cav1.3 1:100 (ACC-005, Alomone), anti-Cav3.1 1:200 (ACC-021, Alomone), anti-Cav3.2 1:200 (ACC-025, Alomone), anti-RyR2 1:1000 (MA3-916, Invitrogen), anti-SERCA 1:200 (sc-30110, Santa Cruz), anti-IP3R 1:500 (ACC-019, Alomone), anti-p(S2814)RyR2 1:5000 (A010-31, Badrilla), anti-phospholamban (PLN) 1:1000 (A010-14, Badrilla), anti-p(T17) PLN 1:5000 (A010-13, Badrilla), HRP-conjugated goat anti-rabbit secondary antibody 1:5000 (Dako, Zug, Switzerland), and HRP-conjugated goat anti-mouse secondary antibody 1:5000 (Dako).

    Techniques: Activity Assay